Jundishapur Journal of Microbiology

Published by: Kowsar

Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran

Zahra Salehei 1 , Zahra Seifi 1 , * and Ali Mahmoudabadi 1 , 2
Authors Information
1 Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Microbiology: September 01, 2012, 5 (4); 574-577
  • Published Online: September 9, 2012
  • Article Type: Research Article
  • Received: February 21, 2012
  • Revised: March 10, 2012
  • Accepted: April 3, 2012
  • DOI: 10.5812/jjm.4556

To Cite: Salehei Z, Seifi Z, Mahmoudabadi A. Sensitivity of Vaginal Isolates of Candida to Eight Antifungal Drugs Isolated From Ahvaz, Iran, Jundishapur J Microbiol. 2012 ; 5(4):574-577. doi: 10.5812/jjm.4556.

Copyright © 2012, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005; 43(5): 2155-62[DOI][PubMed]
  • 2. Ehrstrom S, Yu A, Rylander E. Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol. 2006; 108(6): 1432-7[DOI]
  • 3. Nyirjesy P, Peyton C, Weitz MV, Mathew L, Culhane JF. Causes of chronic vaginitis: analysis of a prospective database of affected women. Obstet Gynecol. 2006; 108(5): 1185-91[DOI]
  • 4. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses. 2006; 49(6): 471-5[DOI][PubMed]
  • 5. Jilek P, Spacek J, Buchta V, Kucera Z, Drahosova M, Forstl M, et al. [Systemic immunity in patients with recurrent vulvovaginal candidiasis]. Ceska Gynekol. 2005; 70(6): 453-9[PubMed]
  • 6. Aali BS, Tohidi A. Prevalence of Candida vaginitis among symptomatic patients in Kerman. J Qazvin Uni Med Sci. 2000; 13: 42-8
  • 7. Aghamirian M, Jahani Hashemi H. Agents associated with candida vulvovaginitis in women referred to health centers in Qazvin. J Qazvin Uni Med Sci. 2007; 11(3): 35-9
  • 8. Jamilian M, Mashadi E, Sarmadi F, Ghaznavi A, Bani Jamali M, Farhadi E, et al. Frequency of vulvovaginal candidiasis species in non-pregnant 15-50 years old women in spring 2005 in Arak. J Arak Uni Med Sci. 2007; 2(10): 7-14
  • 9. Khoursandi M, Modares GM, Khosravi A. Recovery and Recurrence of Vaginal Candidiasis after oral and Intravaginal Treatment. J Qazvin Uni Med Sci. 2000; 14(25): 2
  • 10. Ramezan Zadeh F, Babaei GR, Fakhar F. A survey of oral contraceptive pills (LD) as a cause of Candidial vaginitis. Hakim Res J. 2001; 1(4): 25-30
  • 11. Kamali F, Gharibi T, Naiemi B, Afshary P. Treatment of candida vaginitis: comparison of single and sequential dose of fluconazole. Iranian South Med J. 2003; 6(1): 25-30
  • 12. Kariman NS, Shafaei Z, Afrakhteh M, Valaei N, Ahmadi M. Comparing fluconazole and clotrimazole in treatment of Candida albicans vaginiti. Behbood. 2002; 14(6): 9-16
  • 13. Mohanty S, Xess I, Hasan F, Kapil A, Mittal S, Tolosa JE. Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res. 2007; 126(3): 216-9[PubMed]
  • 14. Momeni A, Shadzi S, Ghadeganipour M, Asilian A, Khorsandi R. The effect of itraconazole on treatment of vaginal candidiasis. J Kerman Uni Med Sci. 1995; 2(2): 71-7
  • 15. Ramezan Zadeh F, Babaei GR, Karbalaei Mohammad S. Comparative study of efficacy of single-dose (500mg) and three days (200mg daily) treatment of candidial vulvovaginitis by vaginal tablets of Clotrimazole. Hakim Res J. 2000; 2(3): 103-8
  • 16. Consolaro ME, Albertoni TA, Svidzinski AE, Peralta RM, Svidzinski TI. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia. 2005; 159(4): 501-7[DOI][PubMed]
  • 17. Mahmoudabadi AZ, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci. 2010; 26(3): 607-10
  • 18. Pakshir K, Bahaedinie L, Rezaei Z, Sodaifi M, Zomorodian K. In vitro activity of six antifungal drugs against clinically important dermatophytes. Jundishapur J Microbiol. 2007; 2(4): 158-63
  • 19. Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006; 44(10): 3578-82[DOI][PubMed]
  • 20. Defontaine A, Bouchara JP, Declerk P, Planchenault C, Chabasse D, Hallet JN. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J Med Microbiol. 1999; 48(7): 663-70[DOI][PubMed]
  • 21. Al-Abeid HM, Abu-Elteen KH, Elkarmi AZ, Hamad MA. Isolation and characterization of Candida spp. in Jordanian cancer patients: prevalence, pathogenic determinants, and antifungal sensitivity. Jpn J Infect Dis. 2004; 57(6): 279-84[PubMed]
  • 22. Quindos G, Abarca L, Carrillo-Munoz AJ, Arevalo MP, Bornay FJ, Casals JB, et al. Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev Iberoam Micol. 1999; 16(2): 97-100[PubMed]
  • 23. Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correlations. J Clin Microbiol. 2000; 38(4): 1563-8[PubMed]
  • 24. Gianni C. Update on antifungal therapy with terbinafine. G Ital Dermatol Venereol. 2010; 145(3): 415-24[PubMed]
  • 25. Barot BS, Parejiya PB, Patel HK, Gohel MC, Shelat PK. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: optimization of formulation using D-optimal design. AAPS Pharm Sci Tech. 2012; 13(1): 184-92[DOI][PubMed]
  • 26. Shivakumar V, Okade R, Rajkumar V, Sajitha K, Prasad SR. Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris. Indian J Dermatol. 2011; 56(1): 121-2[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments